US Stock MarketDetailed Quotes

RVPH Reviva Pharmaceuticals

Watchlist

0.981
-0.069-6.60%

Close Jul 22 16:00 ET

0.971
-0.010-0.99%

Post 17:51 ET

29.24MMarket Cap-616P/E (TTM)

Reviva Pharmaceuticals Stock Forum

Trytosaveabit

Jul 9 07:03

News

$Reviva Pharmaceuticals(RVPH.US)$ Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Trytosaveabit

May 29 15:48

Update

$Reviva Pharmaceuticals(RVPH.US)$ Reviva Announces Closing of $3 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

Trytosaveabit

May 15 07:07

Make a note

$Reviva Pharmaceuticals(RVPH.US)$ Reviva Pharmaceuticals Holdings, Inc. -Topline Data From 1-Year Open-Label Extension (Ole) Trial Expected in Q4 2024

Trytosaveabit

Apr 15 16:16

Update

$Reviva Pharmaceuticals(RVPH.US)$ Reviva Announces Alignment With FDA On Brilaroxazine Clinical Trials For NDA In Schizophrenia; FDA Accepts 4-Week RECOVER-2 Study

Trytosaveabit

Mar 25 05:35

Hmm?

$Reviva Pharmaceuticals(RVPH.US)$ H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report) today and set a price target of $20.00.

Sareus

Jan 16 14:57

$Reviva Pharmaceuticals(RVPH.US)$
$3.50 - $4?
don't mind if I do.

Alvinnnnnnngenius

Jan 8 07:20

This is the next possible amam type move huge potential

$Reviva Pharmaceuticals(RVPH.US)$
$Ambrx Biopharma(AMAM.US)$

Meltyy

Jan 4 01:15

$XBI: Biotech Sector's Potential Outperformance in 2024, Especially Pre-Election Volatility in 1H

$SPDR S&P Biotech ETF(XBI.US)$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...

Moomoo AI

Dec 7, 2023 07:56

Analyst Mohit Bansal opines AbbVie might favour purchasing Cerevel due to its perceived clean IP and daily dosing for its principal schizophrenia medication. He anticipates potential benefit from peak adjustments in sales surpassing $3B.

AbbVie – Cerevel M&A Deal Lifts Reviva, Karuna

Trytosaveabit

Nov 20, 2023 15:07

Update

$Reviva Pharmaceuticals(RVPH.US)$ Press Release: Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Dow Jones· 1 min ago

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall